Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saby George

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial CarcinomaDaniel P Petrylak, Bernhard J Eigl, Saby George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
European Urology|March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaBernard Escudier, Padmanee Sharma, David F McDermott, et al.
Lancet (London, England)|February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Targeted Oncology|September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 TrialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Journal for Immunotherapy of Cancer|November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapyToni K Choueiri, Harriet Kluger, Saby George, et al.
Clinical Genitourinary Cancer|July 10, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 StudyJoshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial CarcinomaDaniel P Petrylak, Bernhard J Eigl, Saby George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialRobert J Motzer, Brian I Rini, David F McDermott, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
European Urology|March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaBernard Escudier, Padmanee Sharma, David F McDermott, et al.
Lancet (London, England)|February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Targeted Oncology|September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 TrialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Journal for Immunotherapy of Cancer|November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapyToni K Choueiri, Harriet Kluger, Saby George, et al.
Clinical Genitourinary Cancer|July 10, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 StudyJoshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, et al.
Pageof 10